Trials / Not Yet Recruiting
Not Yet RecruitingNCT06578286
ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A single arm, phase 2 Study of ARX788 in HER2-positive metastatic breast cancer patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARX788 | ARX788，1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle |
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2026-09-30
- Completion
- 2030-09-30
- First posted
- 2024-08-29
- Last updated
- 2024-08-29
Source: ClinicalTrials.gov record NCT06578286. Inclusion in this directory is not an endorsement.